By Will Boggs, MD NEW YORK (Reuters Health) – Temsirolimus does not improve progression-free survival in metastatic renal cell carcinoma (RCC) compared to standard treatment, according to results…
NEW YORK (Reuters Health) – In patients with potentially resectable colorectal liver metastases, the use of combined PET and CT imaging (PET-CT) identifies those with occult extrahepatic disease…
Recent Videos in Reuters Health • The Doctor’s Channel Newscast Page 130
NEW YORK (Reuters Health) – Putting patients on dialysis before they’re symptomatic offers no survival benefit; on the contrary, it may increase their risk of death, according to…
NEW YORK (Reuters Health) – Patients with acute migraine who find sumatriptan ineffective may have a better response to rizatriptan, according to a study reported in Cephalalgia online…
NEW YORK (Reuters Health) – For women of normal weight or moderate overweight who develop gestational diabetes late in pregnancy, treatment with metformin may be a suitable alternative…
NEW YORK (Reuters Health) – Augmenting antipsychotic treatment with a biologically active natural product, L-theanine, improves symptoms in patients with schizophrenia or schizoaffective disorder, Israeli investigators have shown…
NEW YORK (Reuters Health) – HIV patients whose regimen includes efavirenz and who experience CNS side effects such as insomnia and nervousness may benefit from a switch to…
NEW YORK (Reuters Health) – Hydroxychloroquine may reduce the heightened risk of cardiovascular disease in patients with rheumatoid arthritis. Use of hydroxychloroquine to treat rheumatoid arthritis is associated…
NEW YORK (Reuters Health) – The management of heart failure guided by an individualized target level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) doesn’t lead to clinically significant improvements…
NEW YORK (Reuters Health) – The IL-6 receptor-blocking monoclonal antibody tocilizumab inhibits joint damage in patients with rheumatoid arthritis that is not adequately controlled with methotrexate, according to…
NEW YORK (Reuters Health) – Results of a meta-analysis indicate that moderate doses of inhaled corticosteroids do not have any clinically relevant advantage over low doses in children…
NEW YORK (Reuters Health) – The mineralocorticoid receptor blocker eplerenone has advantages over spironolactone in the treatment of chronic heart failure (CHF), a Japanese team reports. In particular,…
